CoChat

Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C

Open access
Simon, Tracey G., King, Lindsay Y., Zheng, Hui, Chung, Raymond T. · 2015 · Journal of Hepatology
Cited by 114

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background & Aims Therapies that slow fibrosis progression in chronic liver disease are needed. Animal models demonstrate that statins prevent progression of hepatic fibrosis, but human data is lacking. We evaluated the association between statins and fibrosis progression in the HALT-C Trial cohort. Methods Subjects with chronic hepatitis C (CHC) and advanced hepatic fibrosis underwent serial liver biopsies over 3.5 years. The primary outcome was a ≥ 2-point increase in Ishak fibrosis score on at least one of two serial biopsies. We used complementary log-log regression analysis to assess the association between statins and fibrosis progression among subjects without baseline cirrhosis. Results Fibrosis progression occurred in 3/29 (10%) statin users and 145/514 (29%) non-users. The unadjusted hazard ratio (HR) for fibrosis progression among statin users compared to non-users was 0.32 (95% CI 0.10-0.99). This association remained significant after adjusting for established predictors of histological outcome, including body mass index, platelets and hepatic steatosis (adjusted HR 0.31; 95% CI 0.10-0.97). The mean change in Ishak fibrosis score over the 3.5 year study period was -0.34 (SE 0.18) for statin users compared to +0.42 (SE 0.07) for non-users (p= 0.006 after adjustment for baseline fibrosis score). Conclusions Statin use is associated with a reduced risk of fibrosis progression in advanced CHC. Our findings suggest a potential role for statins in preventing liver disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2014.08.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 114

Metadata

Authors
Simon, T. G., King, L. Y., Zheng, H., & Chung, R. T.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2015-01
Volume
62
Issue
1
Pages
18-23
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2033073960
Cited by
114
References
3
FWCI
6.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. https://app.cochat.ai/papers/10.1016/j.jhep.2014.08.013
The paper
Simon, T. G., King, L. Y., Zheng, H., & Chung, R. T. (2015). Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2014.08.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.